CEPTAZ
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEPTAZ is an injectable small-molecule product approved by GSK in 1990 for use via intramuscular or intravenous injection. The exact mechanism of action and therapeutic indication are not publicly detailed in available data, limiting assessment of clinical positioning. As a 34-year-old NDA product, CEPTAZ represents a mature, established therapy in its lifecycle.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the commercial team is likely in defensive/transition mode, potentially reducing headcount in brand management and field sales.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEPTAZ presents limited career growth opportunity; the product is in LOE phase with zero linked job postings and no active clinical pipeline. Roles available are primarily defensive, focused on market maintenance and customer retention rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on CEPTAZ at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.